We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+1.74%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.1B
AUM Growth
+$59.7M
Cap. Flow
-$1.53B
Cap. Flow %
-21.52%
Top 10 Hldgs %
75.68%
Holding
101
New
15
Increased
16
Reduced
17
Closed
6

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$78.6M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$57.7M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$22.5M
4
DYAX
DYAX CORPORATION
DYAX
+$15.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.6M

Top Sells

Rank Stock Value
1
VPHM
VIROPHARMA INC
VPHM
+$220M
2
GILD icon
Gilead Sciences
GILD
+$48M
3
PCYC
PHARMACYCLICS INC
PCYC
+$35.3M
4
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$24.5M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$24.5M

Sector Composition

Rank Sector Weight
1 Healthcare 50.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$922M 13%
8,719,218
-290,993
-3% -$35.3M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$827M 11.66%
20,735,926
+1,412,979
+7% +$57.7M
INCY icon
3
Incyte
INCY
$25.9B
$750M 10.57%
14,810,559
– –
GEVA
4
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$665M 9.37%
10,273,182
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$5.08B
$499M 7.03%
19,955,126
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$400M 5.63%
13,650,835
– –
XOMA
7
DELISTED
Xoma
XOMA
$155M 2.18%
1,151,619
– –
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12.9B
$137M 1.92%
1,941,304
+1,157,993
+148% +$78.6M
HALO icon
9
Halozyme
HALO
$12.3B
$94.4M 1.33%
6,297,026
-720,582
-10% -$9.27M
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$319M
$59.5M 0.84%
4,791,179
– –
CERS icon
11
Cerus
CERS
$566M
$54.5M 0.77%
8,455,306
– –
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.44B
$50.9M 0.72%
6,699,979
– –
RPRX
13
DELISTED
Repros Therapeutics Inc.
RPRX
$50.8M 0.72%
2,778,654
– –
QCOR
14
DELISTED
QUESTCOR PHARMA INC
QCOR
$42.2M 0.6%
775,864
+230,018
+42% +$13.6M
ANAC
15
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$42M 0.59%
2,500,000
+1,623,537
+185% +$22.5M
GILD icon
16
Gilead Sciences
GILD
$181B
$41.8M 0.59%
556,108
-689,692
-55% -$48M
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$39.6M 0.56%
2,380,074
+400,000
+20% +$6.84M
AEGR
18
DELISTED
Aegerion Pharmaceuticals
AEGR
$35.5M 0.5%
500,000
-320,275
-39% -$24.5M
ARWR icon
19
Arrowhead Research
ARWR
$12.3B
$33.5M 0.47%
3,090,000
-50,000
-2% -$400K
CLVS
20
DELISTED
Clovis Oncology, Inc.
CLVS
$32M 0.45%
530,738
+228,994
+76% +$12.5M
DSCI
21
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$27.7M 0.39%
2,558,857
– –
CHTP
22
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$25.7M 0.36%
5,794,753
– –
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
$25.4M 0.36%
796,662
– –
ICPT
24
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$24.8M 0.35%
362,847
– –
PGNX
25
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$22.4M 0.32%
4,200,000
– –
1
2 3 4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2013 Portfolio in Review

As of Q4 2013, Julian Baker held 101 positions worth $7.1B, up 0.85% from $7.04B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Julian Baker withdrew a net $1.53B in Q4 2013, closing 6 positions and reducing 17 holdings. Its most notable exit was VIROPHARMA INC, an estimated $220M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 48% a quarter earlier.

Against the trend, Julian Baker opened a new position in DYAX CORPORATION worth $15.3M.

  • Julian Baker's largest Q4 2013 buy was DYAX CORPORATION: 2,026,537 shares worth $15.3M.
  • Julian Baker added most to BioMarin Pharmaceuticals in Q4 2013, an estimated $78.6M increase.
  • Julian Baker's biggest Q4 2013 reduction was Gilead Sciences, cutting an estimated $48M.
  • Julian Baker fully exited VIROPHARMA INC in Q4 2013, selling an estimated $220M.
  • Julian Baker's ten largest holdings make up 76% of its $7.1B portfolio in Q4 2013.
  • Julian Baker opened 15 new positions and closed 6 in Q4 2013.
  • Julian Baker's portfolio value rose 0.85% quarter-over-quarter to $7.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.